300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Cryptocurrency
Digital Media
Oil and Gas
Retail
Film
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Social Media
Manufacturing
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Mozambique
Mauritius
Namibia
Nicaragua
Panama
Serbia
Morocco
Uzbekistan
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
New Zealand
Venezuela
Myanmar
Uganda
Moldova
Uruguay
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Iraq
Ghana
Philippines
Sierra Leone
El Salvador
Senegal
Portugal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Bangladesh
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Bolivia
Jersey
Estonia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

Ken Newport

Angel Investor

Ken Newport is a angel investor focused on Life Science and Biotechnology. Ken Newport was appointed to Jennerex's board in 2007. A chartered accountant, entrepreneur and life sciences business executive, Mr. Newport served as senior vice president and executive committee member at PRA International Inc. for three years until his retirement in 2005. In the mid-nineties he was co-founder and president of CroMedicaInc., a clinical trials contract research organization which was sold to PRA International in 2002. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is a member of the Institute of Corporate Directors and also serves on the corporate boards of The Opmedic Group and Medgenesis Therapeutics Inc. Mr. Newport earned Honours B.A. and Masters of Accounting degrees from the University of Waterloo.

Total investments:
1
Last investment:
Lead investor:
100%

Last updated:

Industries Ken Newport invests in

Life ScienceBiotechnology

Stages Ken Newport invests in

Angel

Countries Ken Newport invests in

Canada

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Life Science 1 (100%)
  • Biotechnology 1 (100%)

Investments

CompanyDescriptionRoundLinks
Rhythm Biotherapeutics is a preclinical-stage firm that aims to solve a key unmet need by preventing and treating atrial fibrillation, a chronic, progressive, debilitating, and life-threatening condition. Our initial focus is on a preventative solution for postoperative atrial fibrillation. RBex is a preventive exosome treatment that has shown an87% reduction in postoperative atrial fibrillation in comprehensive and published preclinical trials. We are now soliciting funds to conduct a first-in-human phase 1 clinical trial. $235K / Angel / Jan 01, 2023

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Cryptocurrency
Digital Media
Oil and Gas
Retail
Film
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Social Media
Manufacturing
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Mozambique
Mauritius
Namibia
Nicaragua
Panama
Serbia
Morocco
Uzbekistan
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
New Zealand
Venezuela
Myanmar
Uganda
Moldova
Uruguay
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Iraq
Ghana
Philippines
Sierra Leone
El Salvador
Senegal
Portugal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Bangladesh
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Bolivia
Jersey
Estonia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Ken Newport invest in?

Ken Newport invests primarily in Life Science and Biotechnology startups, most often at Angel stage. Most of the 1 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Ken Newport?

Public channels for Ken Newport include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Ken Newport last invest?

The most recent investment recorded for Ken Newport closed in Jan 2023. Shizune tracks 1 investment in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Ken Newport Find email